Showing 6201-6210 of 7021 results for "".
- Novan, Inc. Launches IPO, Lists on NASDAQhttps://practicaldermatology.com/news/novan-inc-launches-ipo-lists-on-nasdaq/2458429/Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- GLOWBIOTICS MD is New Name of mybody Probiotic Skincarehttps://practicaldermatology.com/news/glowbiotics-md-is-new-name-of-mybody-probiotic-skincare/2458440/GLOWBIOTICS MD is the new name of mybody Probiotic Skincare. Currently carried in over 1,000 doctors’ offices across the country and internationally, the five-year-old brand is the first medical-grade
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).
- Sensus Healthcare Receives Frost & Sullivan 2016 Global NMSC Therapy Technology Leadership Awardhttps://practicaldermatology.com/news/sensus-healthcare-inc-receives-frost-sullivan-2016-global-nmsc-therapy-technology-leadership-award/2458443/Sensus Healthcare, Inc. has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Tec
- Mass Spectrometry Test Helps Distinguish Atypical Moles From Melanomahttps://practicaldermatology.com/news/mass-spectrometry-test-helps-distinguish-atypical-moles-from-melanoma/2458447/Mass spectrometry may aid in the diagnosis of atypical moles, new research suggests. In this study, mass spectrometry, which analyzes the level of proteins within mole cells, correlated better than the gold standard of histologic examination to determine if an atypical mole was benign or
- Hair Transplants Make Men Look Younger, Hotterhttps://practicaldermatology.com/news/hair-transplants-make-men-look-younger-hotter/2458450/Once-balding men who undergo hair transplants are seen as more youthful, attractive, successful and approachable, new research suggests. In 2014, hair transplant was among the most common cosmetic services sought by men, with more than 11, 000 procedures performed, according to info
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated
- Fractional HiFR Helps Fight Signs of Aging on Lower Face/Neckhttps://practicaldermatology.com/news/fractional-hifr-helps-fight-signs-of-aging-on-lower-faceneck/2458469/Fractional high intensity focused radiofrequency (HiFR) is safe and effective in the treatment of mild to moderate laxity of the lower face and neck, new research suggests. The study was selected as Editor’s Choice in the July 2016 issue of